KGYY-15(KGYY-15) - 药物靶点：CD40 x CD40L_在研适应症：1型糖尿病，多发性硬化症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点

CD40 x CD40L

作用机制

CD40抑制剂(肿瘤坏死因子受体超家族成员5抑制剂)、CD40L抑制剂(CD40配体抑制剂)

治疗领域

免疫系统疾病内分泌与代谢疾病神经系统疾病+ [1]

在研适应症

1型糖尿病多发性硬化症

非在研适应症-

原研机构

University of Colorado System

在研机构

University of Colorado SystemOp-T-Mune, Inc

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 KGYY-15 相关的临床结果

登录后查看更多信息

100 项与 KGYY-15 相关的转化医学

登录后查看更多信息

100 项与 KGYY-15 相关的专利（医药）

登录后查看更多信息

1

项与 KGYY-15 相关的文献（医药）

2023-05-01·Journal of Biological Chemistry

Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY15

Article

作者: Wagner, David H ; Vaitaitis, Gisela M

CD40 signaling has long been a target in autoimmunity. Attempts to block signaling between CD40 and CD154 during clinical trials using monoclonal antibodies suffered severe adverse events. Previously, we developed a peptide, KGYY₁₅, that targets CD40 and, in preclinical trials, prevents type 1 diabetes in >90% of cases and reverses new-onset hyperglycemia in 56% of cases. It did so by establishing normal effector T-cell levels rather than ablating the cells and causing immunosuppression. However, the relationship between KGYY₁₅ and other elements of the complex signaling network of CD40 is not clear. Studying interactions between proteins from autoimmune and nonautoimmune mice, we demonstrate interactions between CD40 and integrin CD11a/CD18, which complicates the understanding of the inflammatory nexus and how to prevent autoinflammation. In addition to interacting with CD40, KGYY₁₅ interacts with the integrins CD11a/CD18 and CD11b/CD18. We argue that modulation of CD40-CD154 signaling may be more advantageous than complete inhibition because it may preserve normal immunity to pathogens.

100 项与 KGYY-15 相关的药物交易

登录后查看更多信息